Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

NCT06630221 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia

Interventions

DRUG: Eltrombopag (EPAG)

Sponsor

Abhay Singh, MD MPH